U.S.C. homeSearch U.S. Code
U.S. CodeTitle 21Chapter 9— Federal Food, Drug, And Cosmetic ActSubchapter I— Short Title

21 U.S.C. § 301 (2026)

Short title

Edition and currency
U.S. Code current through Pub. L. 119-102 (OLRC release point). The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTU.S. Code current through Pub. L. 119-102 (OLRC release point) cited 1942–2026 1,640citing cases
At a glance

Courts have cited this section in 1,640 opinions since 1942, 236 of them in the last five years.

This chapter may be cited as the Federal Food, Drug, and Cosmetic Act.

(June 25, 1938, ch. 675, § 1, 52 Stat. 1040.)
The 20 cases that cite 21 U.S.C. § 301 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENRiegel v. Medtronic, Inc., 552 U.S. 312 (2008).
cites § 301 6×cited by 725 cases
Where it cites § 301
“1040 , as amended, 21 U.S.C. § 301 et seq., has long required FDA approval for the introduction of new drugs into the market.”
The case’s holding
The Medical Device Amendments preclude state law claims that impose requirements different from, or in addition to, federal requirements regarding a device that received premarket approval.
Later courts cite it for
“360k does not prevent a state from providing a damages remedy for claims premised on a violation of fda regulations; the state duties in such a case 'parallel,' rather than add to, federal requirements.” · 102 citing courts
cites § 301 4×cited by 2,173 cases
Where it cites § 301
“1040 , as amended, 21 U. S. C. § 301 et seq. (1982 ed. and Supp.”
The case’s holding
Federal question jurisdiction does not exist over state tort claims based on a federal statute when the federal issue is not necessarily determinative of the state law claim.
Later courts cite it for
“the mere presence of a federal issue in a state cause of action does not automatically confer federal-question jurisdiction.” · 268 citing courts
3
GREENHolly Vanzant v. Hill's Pet Nutrition, Incorpo, 934 F.3d 730 (7th Cir. 2019).
cites § 301 2×cited by 235 cases
Where it cites § 301
“Under the Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301 et seq. , pet food intended to treat or prevent disease and marketed as such is considered a drug and requires approval of a new animal drug application.”
The case’s holding
FDA guidance regarding enforcement discretion does not constitute specific regulatory authorization under a state consumer fraud safe-harbor provision.
Later courts cite it for
“that the defendant committed a deceptive or unfair act with the intent that others rely on the deception, that the act occurred in the course of trade or commerce, and that it caused actual damages.” · 27 citing courts
4
GREENWyeth v. Levine, 555 U.S. 555 (2009).
cites § 301 2×cited by 1,273 cases
Where it cites § 301
“1040 , as amended, 21 U.S.C. § 301 et seq. The Act's most substantial innovation was its provision for premarket approval of new drugs.”
The case’s holding
FDA approval of a drug label does not preempt state law failure-to-warn claims because federal regulations allow manufacturers to strengthen warnings without prior agency approval.
Later courts cite it for
“clear evidence that the fda would not have approved a change to the drug's label.” · 41 citing courts
5
GREENBuckman Co. v. Plaintiffs' Legal Comm., 531 U.S. 341 (2001).
cites § 301 2×cited by 935 cases
Where it cites § 301
“539 , 21 U. S. C. § 301 (1994 ed. and Supp. V).”
The case’s holding
State law claims alleging fraud on the FDA are impliedly preempted by federal law because they interfere with the agency's responsibility to police fraud according to its own objectives.
Later courts cite it for
“the fdca leaves no doubt that it is the federal government rather than private litigants who are authorized to file suit for noncompliance with the medical device provisions.” · 87 citing courts
6
GREENRiegel v. Medtronic, Inc., 451 F.3d 104 (2d Cir. 2006).
cites § 301 4×cited by 104 cases
Where it cites § 301
“______________ KATZMANN , Circuit Judge: This case calls upon us to determine, inter alia, the scope of the preemption provision set forth in Section 360k(a) of the 1976 Medical Device Amendments to the Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301 et. seq. Specifically, we…”
The case’s holding
State common law tort claims alleging liability based on a medical device's adherence to FDA premarket approval standards are preempted by the Medical Device Amendments.
Later courts cite it for
“an expert opinion requires some explanation as to how the expert came to his conclusion and what methodologies or evidence substantiate that conclusion.” · 26 citing courts
7
GREENSarah Speed v. Wyeth Pharm., Inc., 737 F.3d 378 (6th Cir. 2013).
cites § 301 4×cited by 77 cases
Where it cites § 301
“The makers of the generic metoclopramide moved to dismiss the claims against them, arguing that all of the plaintiffs’ claims are preempted by the Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. §§ 301 -399f, under the Supreme Court decision in PLIVA, Inc.”
The case’s holding
State-law failure-to-warn claims against generic drug manufacturers are preempted by federal law because generic manufacturers must use labels identical to the brand-name drug.
Later courts cite it for
“despite the 'catch-22' dilemma” · 3 citing courts
8
GREENHaudrich v. Howmedica, Inc., 662 N.E.2d 1248 (Ill. 1996).
cites § 301 4×cited by 252 cases
Where it cites § 301
“The appellate court rejected this contention, holding instead that the United States Congress did not intend to preempt common law tort actions by passing the Medical Device Amendments.”
The case’s holding
Issues not raised during a trial are deemed waived and cannot be raised for the first time on appeal.
Later courts cite it for
“it is well settled that issues not raised in the trial court are deemed waived and may not be raised for the first time on appeal.” · 73 citing courts
9
GREENHeckler v. Chaney, 470 U.S. 821 (1985).
cites § 301 2×cited by 2,449 cases
Where it cites § 301
“1040 , as amended, 21 U. S. C. § 301 et seq. (FDCA), and requesting that the FDA take various enforcement actions to prevent these violations.”
The case’s holding
An agency decision not to enforce is generally committed to its absolute discretion and is unreviewable unless the governing statute provides meaningful standards for judicial review.
Later courts cite it for
“review is not to be had if the statute is drawn so that a court would have no meaningful standard against which to judge the agency's exercise of discretion.” · 362 citing courts
cites § 301 2×cited by 1,925 cases
Where it cites § 301
“1040 , as amended, 21 U. S. C. § 301 et seq., and that cigarettes and smokeless tobacco are "combination products" that deliver nicotine to the body.”
The case’s holding
Statutory provisions must be interpreted in the context of the overall regulatory scheme and the expressed intent of Congress.
Later courts cite it for
“the meaning - or ambiguity - of certain words or phrases may only become evident when placed in context.” · 137 citing courts
11
GREENJones v. Rath Packing Co., 430 U.S. 519 (1977).
cites § 301 2×cited by 1,454 cases
Where it cites § 301
“1040 , as amended, *533 21 U. S. C. § 301 et seq., and the Fair Packaging and Labeling Act (FPLA), 80 Stat.”
The case’s holding
Obstacle preemption requires analyzing the relationship between state and federal laws as they are interpreted and applied rather than merely as they are written.
Later courts cite it for
“is compelled whether congress' command is explicitly stated in the statute's language or implicitly contained in its structure and purpose.” · 84 citing courts
12
GREENDumont v. Reily Foods Co., 934 F.3d 35 (1st Cir. 2019).
cites § 301 2×cited by 65 cases
Where it cites § 301
“The defendants propose one additional alternative ground for affirming the dismissal of Dumont's complaint: Even if the complaint alleges a claim under chapter 93A, they argue, that claim is impliedly preempted by the Federal Food, Drug, and Cosmetic Act [FDCA], 21 U.S.C. § 301…”
The case’s holding
A consumer complaint sufficiently pleads fraud under Rule 9(b) by identifying the specific misleading label and the product sold, provided the allegations make the claim of deception plausible.
Later courts cite it for
“to place the defendants on notice and enable them to prepare meaningful responses, to preclude the use of a groundless fraud claim as pretext for discovering a wrong, and to safeguard defendants from frivolous charges that might damage their reputation.” · 6 citing courts
13
GREENEbner v. Fresh, Inc., 838 F.3d 958 (9th Cir. 2016).
cites § 301 1×cited by 446 cases
Where it cites § 301
“In dismissing the label-based claims, the district court concluded that both California’s safe harbor doctrine and federal preemption under the Food, Drug, and Cosmetic Act (“FDCA”), 21 U.S.C. §301 et seq., were independently fatal to Plaintiffs claims.”
The case’s holding
A claim for deceptive packaging is plausible only if the plaintiff alleges facts showing that a significant portion of the consuming public would be misled.
Later courts cite it for
“the reasonable consumer standard requires a probability that a significant portion of the general consuming public or of targeted consumers, acting reasonably in the circumstances, could be misled.” · 66 citing courts
14
GREENMut. Pharm. Co. v. Bartlett, 570 U.S. 472 (2013).
cites § 301 2×cited by 246 cases
Where it cites § 301
“1040 , as amended, 21 U.S.C. § 301 et seq., drug manufacturers must gain approval from the United States Food and Drug Administration (FDA) before marketing any drug in interstate commerce.”
The case’s holding
State-law design-defect claims based on inadequate warnings are preempted when federal law prohibits generic drug manufacturers from unilaterally changing labels to comply with state requirements.
Later courts cite it for
“an actor seeking to satisfy both his federal- and state-law obligations is not required to cease acting altogether in order to avoid liability.” · 18 citing courts
15
GREENDavid Zink v. George Lombardi, 783 F.3d 1089 (8th Cir. 2015).
cites § 301 2×cited by 227 cases
Where it cites § 301
“The prisoners complain that the use of compounded pentobarbital as a lethal drug in executions violates the federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301 , et seq., and the Controlled Substances Act.”
The case’s holding
A complaint must contain sufficient factual matter to state a plausible claim that an execution protocol creates a substantial risk of severe pain and that a feasible alternative exists.
Later courts cite it for
“threadbare recitals of the elements of a cause of action, supported by mere conclusory statements, do not suffice.” · 32 citing courts
16
GREENRoyal Canin U. S. A. v. Wullschleger, 604 U.S. 22 (2025).
cites § 301 1×cited by 304 cases
Where it cites § 301
“It also alleged viola- tions of the Federal Food, Drug, and Cosmetic Act (FDCA), 21 U. S. C. §301 et seq. And so began the procedural back-and-forth that eventu- ally landed Wullschleger’s case in this Court.”
The case’s holding
A district court should decline supplemental jurisdiction and remand a case to state court once all claims over which it has original jurisdiction are dismissed.
Later courts cite it for
“if a plaintiff amends her complaint, the new pleading 'supersedes' the old one: the 'original pleading no longer performs any function in the case.” · 40 citing courts
17
GREENGardner v. Toilet Goods Assn., Inc., 387 U.S. 167 (1967).
cites § 301 4×cited by 433 cases
Where it cites § 301
“1040 , as amended), 21 U. S. C. § 301 et seq., that precludes resort to the courts for pre-enforcement relief under the Administrative Procedure Act, 5 U.”
The case’s holding
Pre-enforcement judicial review is appropriate when regulations are self-executing and have an immediate and substantial impact on the regulated parties.
Later courts cite it for
“immediate and substantial impact” · 4 citing courts
18
GREENGibbons v. Bristol-Myers Squibb Co., 919 F.3d 699 (2d Cir. 2019).
cites § 301 1×cited by 256 cases
Where it cites § 301
“Dismissal Plaintiffs also challenge the district court's dismissal of the remaining sixty-four suits - fifteen of which are now before us - on the grounds that their failure-to-warn claims are preempted by the FDCA.”
The case’s holding
The forum defendant rule under 28 U.S.C. § 1441(b)(2) is inapplicable until a home-state defendant has been properly joined and served.
Later courts cite it for
“by its text, then, section 1441(b)(2) is inapplicable until a home-state defendant has been served in accordance with state law; until then, a state court lawsuit is removable under section 1441(a) so long as a federal district court can assume jurisdiction over the action.” · 27 citing courts
19
cites § 301 4×cited by 28 cases
Vacated: 2 citing opinions add another limit ("vacated (caution)").
Where it cites § 301
“The Food, Drug, and Cosmetic Act ("FDCA"), 21 U.S.C. § 301 , et seq., requires that applicants for new drug applications submit "[c]opies of the label and all labeling for the drug product," 21 C.”
Later courts cite it for
“promotional campaign for vioxx,” · 2 citing courts
20
GREENT.H. v. Novartis Pharm. Corp., 4 Cal. 5th 145 (2017).
cites § 301 1×cited by 226 cases
Where it cites § 301
“Federal Regulation of Drug Labeling The Food, Drug, and Cosmetic Act (FDCA; 21 U.S.C. § 301 et seq. ) prohibits the marketing of a new brand-name drug unless the manufacturer has submitted a new drug application (NDA) and the Food and Drug Administration (FDA) has approved the…”
The case’s holding
A brand-name drug manufacturer owes a duty of care to ensure warning labels are adequate for users of both brand-name and generic bioequivalent drugs.
Later courts cite it for
“in reviewing an order sustaining a demurrer, we examine the operative complaint de novo to determine whether it alleges facts sufficient to state a cause of action under any legal theory.” · 52 citing courts

Show all 1,640 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
194219842026

One bar per 2 years. Tallest: 104 cases in 2020–2021. 2026 is a partial year. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.D.C.123S.D.N.Y.729th Cir.68D.C. Cir.52D.N.J.472d Cir.46N.D. Cal.41E.D.N.Y40

The 8 courts with the most citing cases, of 166 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Show all 1,640 citing cases (list view) →

Enactment and amendments
(June 25, 1938, ch. 675, § 1, 52 Stat. 1040.)
Versions

Edition shown: U.S. Code current through Pub. L. 119-102 (OLRC release point). Syfert holds no earlier or later version of this section.

U.S.C. Home  |  Search U.S. Code  |  Search cases for this section  |  syfert.com